4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Elutia Inc. (ELUT) operates in the Medical Devices industry and is headquartered in Gaithersburg, United States with about 25 employees. Its market capitalization is roughly $42 million. In the fiscal year ended 2025-12-31, ELUT reported $12M in revenue and $53M in net income.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Interactive charts & full statements → Open the ELUT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $12M | $14M | $25M | $24M | — |
| Gross Profit | $7M | $7M | $11M | $12M | — |
| Operating Income (EBIT) | ($18M) | ($19M) | ($20M) | ($30M) | — |
| Net Income | $53M | ($54M) | ($38M) | ($33M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $3M | $3M | $3M | $6M | $3M | — |
| Gross Profit | $2M | $2M | $2M | $3M | $1M | — |
| Operating Income (EBIT) | ($6M) | ($6M) | ($4M) | ($6M) | ($4M) | — |
| Net Income | ($8M) | $71M | ($4M) | ($10M) | ($4M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $62M | $36M | $43M | $69M | — |
| Total Liabilities | $35M | $82M | $82M | $74M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELUT viewer.
About TickerBase · Data methodology & sources